Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(17%)
Results Posted
33%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
3
50%
Ph phase_2
2
33%
Ph not_applicable
1
17%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
3(50.0%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
unknown1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (33.3%)
Phase 33 (50.0%)
N/A1 (16.7%)

Trials by Status

unknown117%
recruiting117%
terminated117%
completed350%

Recent Activity

1 active trials
Showing 5 of 6
completedphase_2

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931
recruitingphase_3

Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.

NCT05063149
terminatedphase_2

Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

NCT05222516
completedphase_3

Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85

NCT04496245
unknownnot_applicable

Efficacy and Safety of Broncho-Vaxom in the First Episode of Pediatric Idiopathic Nephrotic Syndrome

NCT05044169
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04129931Phase 2

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Completed
NCT05063149Phase 3

Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.

Recruiting
NCT05222516Phase 2

Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

Terminated
NCT04496245Phase 3

Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85

Completed
NCT05044169Not Applicable

Efficacy and Safety of Broncho-Vaxom in the First Episode of Pediatric Idiopathic Nephrotic Syndrome

Unknown
NCT03047954Phase 3

Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6